Aurobindo Pharma shares in focus after US FTC approves $250 million Lannett Co. acquisition move

Aurobindo Pharma shares are set to be in focus of stock market investors on Monday, June 22, after the company received US Federal Trade Commission (FTC) approval to proceed with its $250 million plan to acquire Lannett Company LLC.

“Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission to proceed with the acquisition of Lannett Company LLC,” the company informed the stock exchanges.

$250 million deal details

As per the NSE filing, Aurobindo Pharma will acquire Lannett Co. via a transaction valued at $250 million on a cash-free, debt-free basis and inclusive of normalised working capital. The acquisition is expected to close by the end of June 2026.

Lannett Company’s manufacturing facility in Seymour, Indiana, United States, has the capacity to strengthen Aurobindo USA’s manufacturing footprint to approximately 4 billion doses per year.

“This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production,” Aurobindo Pharma said.

The company also disclosed that the acquisition is estimated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages, while enhancing the differentiated pipeline of complex generics and controlled substances.

“It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances,” said Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA.

“We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion.”

Lannett Company LLC is a US-based pharma company which is focused on the development and commercialisation of complex generic pharmaceutical products, including non-opioid controlled substances.

How have Aurobindo Pharma shares performed?

Aurobindo Pharma shares closed 3.75% higher at ₹1,497.80 after Friday’s trading session last week, compared to ₹1,443.70 at the previous stock market close, according to NSE data. The company announced its FTC approval update before the market opening on Monday, June 22.

Shares of Aurobindo Pharma have delivered investors more than 57% returns on their investment in last five years, over 123% gains in the last three years, and more than 36% returns in the past one-year period.

As per the exchange data, the pharma company shares have gained 25% year-to-date in the calendar year 2026, and 2.4% in the last one month. Aurobindo Pharma shares were trading 6.4% higher over the last five market sessions on NSE.

Aurobindo Pharma shares hit their 52-week high of ₹1,550 on May 21, 2026, while the 52-week low was at ₹1,016.10 on September 1, 2025, as per the exchange data. The company’s market capitalisation (m-cap) was at ₹86,277 crore as of the stock market close on Friday.